postponed plan and slow down investment, From such situations effected Company performance for quarterly2 2017 as follow; - Decreased on sales from Baht 226.04M in Q2’2016 to Baht 172.88M in Q2’2017 at 23.52

subsidiaries have the revenues from medical treatment of 796.27 million baht, which is a 0.15 % increase from the previous year. The revenues can from the two hospitals are broken down as follows

overdrafts and short-term loan outstanding for the three-month period financial statement ended March 31, 2018. A part of the proceeds from the disposal of assets were used to pay down on the bank overdrafts

conditions stated therein. The proposed sell-down of the Units is strictly a f inancing exercise to fund, amongst other things, working capital needs and to pay the Company’s indebtedness and liabilit ies

stated therein. The sale price was determined through a book building process. The proposed sell-down of the Units is strictly a financing exercise to fund, amongst other things, working capital needs and

subsidiaries have the revenues from medical treatment of 977.49 million baht, which is a 3.13 % increase from the previous year. The revenues can from the three hospitals are broken down as follows

API 2019 The Securities and Exchange Commission, Thailand. All rights reserved. This website is best viewed with Microsoft Edge, Chrome, Safari and Firefox. Sitemap Privacy Policy Disclaimer Take Down

website is best viewed with Microsoft Edge, Chrome, Safari and Firefox. Sitemap Privacy Policy Disclaimer Take Down Notice

Firefox. Sitemap Privacy Policy Disclaimer Take Down Notice

Commission, Thailand. All rights reserved. This website is best viewed with Microsoft Edge, Chrome, Safari and Firefox. Sitemap Privacy Policy Disclaimer Take Down Notice